<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Database (Oxford)</journal-id>
    <journal-id journal-id-type="iso-abbrev">Database (Oxford)</journal-id>
    <journal-id journal-id-type="publisher-id">databa</journal-id>
    <journal-title-group>
      <journal-title>Database: The Journal of Biological Databases and Curation</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1758-0463</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
      <publisher-loc>UK</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9684616</article-id>
    <article-id pub-id-type="doi">10.1093/database/baac101</article-id>
    <article-id pub-id-type="publisher-id">baac101</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00960</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>HCDT: an integrated highly confident drugâ€“target resource</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2284-379X</contrib-id>
        <name>
          <surname>Chen</surname>
          <given-names>Jiaqi</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
        <xref rid="FN01" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Zhengxin</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
        <xref rid="FN01" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Rufei</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Feng</surname>
          <given-names>Dehua</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Tianyi</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Han</surname>
          <given-names>Huirui</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bi</surname>
          <given-names>Xiaoman</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Zhenzhen</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Kongning</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1914-0727</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Yongsheng</given-names>
        </name>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9794-2648</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Xia</given-names>
        </name>
        <!--lixia@hrbmu.edu.cn-->
        <xref rid="COR0001" ref-type="corresp"/>
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
        <aff><institution content-type="department">College of Bioinformatics Science and Technology, Harbin Medical University</institution>, Harbin, 150086, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Wang</surname>
          <given-names>Limei</given-names>
        </name>
        <xref rid="COR0001" ref-type="corresp"/>
        <!--wanglm@hainmc.edu.cn-->
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6131-456X</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Jin</given-names>
        </name>
        <xref rid="COR0001" ref-type="corresp"/>
        <!--lijin@hainmc.edu.cn-->
        <aff><institution content-type="department">Key Laboratory of Tropical Translational Medicine of Ministry of Education, Bioinformatics for Major Diseases Science Innovation Group, College of Biomedical Informatics and Engineering, Hainan Medical University</institution>, Haikou 571199, <country country="CN">China</country></aff>
        <aff><institution content-type="department">College of Bioinformatics Science and Technology, Harbin Medical University</institution>, Harbin, 150086, <country country="CN">China</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR0001">*Corresponding author: Tel: +86-451-86615922; Fax: +86-451-86615922; Email: <email xlink:href="lixia@hrbmu.edu.cn">lixia@hrbmu.edu.cn</email> Correspondence may also be addressed to Limei Wang. Tel: +86-898-66893770; Fax: +86-898-66893770; Email: <email xlink:href="wanglm@hainmc.edu.cn">wanglm@hainmc.edu.cn</email> and Jin Li. Tel: +86-898-66893770; Fax: +86-898-66893770; Email: <email xlink:href="lijin@hainmc.edu.cn">lijin@hainmc.edu.cn</email></corresp>
      <fn id="FN01">
        <label>â€ </label>
        <p>have contributed equally to this work and share first authorship.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-11-24">
      <day>24</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>24</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <volume>2022</volume>
    <elocation-id>baac101</elocation-id>
    <history>
      <date date-type="received">
        <day>29</day>
        <month>7</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>10</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>01</day>
        <month>11</month>
        <year>2022</year>
      </date>
      <date date-type="editorial-decision">
        <day>24</day>
        <month>10</month>
        <year>2022</year>
      </date>
      <date date-type="corrected-typeset">
        <day>24</day>
        <month>11</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© The Author(s) 2022. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="baac101.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Drugâ€“target association plays an important role in drug discovery, drug repositioning, drug synergy prediction, etc. Currently, a lot of drug-related databases, such as DrugBank and BindingDB, have emerged. However, these databases are separate, incomplete and non-uniform with different criteria. Here, we integrated eight drug-related databases; collected, filtered and supplemented drugs, target genes and experimentally validated (highly confident) associations and built a highly confident drugâ€“target (HCDT: <ext-link xlink:href="http://hainmu-biobigdata.com/hcdt" ext-link-type="uri">http://hainmu-biobigdata.com/hcdt</ext-link>) database. HCDT database includes 500â€‰681 HCDT associations between 299â€‰458 drugs and 5618 target genes. Compared to individual databases, HCDT database contains 1.1 to 254.2 times drugs, 1.8â€“5.5 times target genes and 1.4â€“27.7 times drugâ€“target associations. It is normative, publicly available and easy for searching, browsing and downloading. Together with multi-omics data, it will be a good resource in analyzing the drug functional mechanism, mining drug-related biological pathways, predicting drug synergy, etc.</p>
      <p><bold>Database URL</bold>: <ext-link xlink:href="http://hainmu-biobigdata.com/hcdt" ext-link-type="uri">http://hainmu-biobigdata.com/hcdt</ext-link></p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Hainan Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004761</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>621MS041</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Hainan Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004761</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>821MS045</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Hainan Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004761</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>821MS0777</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Hainan Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004761</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>822MS074</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>31701159</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32160179</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32260155</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Major Science and Technology Program of Hainan Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>ZDKJ202003</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="7"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="s2">
    <title>Introduction</title>
    <p>Drug discovery is a time-consuming, costly and risky process (<xref rid="R1" ref-type="bibr">1</xref>). According to a report published in 2021, the average time to develop a new drug from clinical trials to market was 7.5â€‰years (<xref rid="R2" ref-type="bibr">2</xref>). With clinical development proceeding from Phase 1 to Phases 2 and 3, the average cost per study increased for all therapeutic areas. However, the average success rate for developing new drugs was only 2.01% (<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>). The annual investment in drug development has gradually increased, even while the number of Food and Drug Administration-approved drugs has been declining since 1995 (<xref rid="R4" ref-type="bibr">4</xref>). Between 2009 and 2018, the median cost of developing a new drug was $985 million, while the average sum totaled $1.3 billion. In all therapeutic areas, oncology and immunomodulatory drugs were the most expensive to develop, coming in at a median of $2.8 billion and a mean of $4.5 billion (<xref rid="R5" ref-type="bibr">5</xref>).The cost of new drug development will continue to grow. Hence, it is urgent to find a new strategy to discover drugs (<xref rid="R1" ref-type="bibr">1</xref>).</p>
    <p>Drug repositioning (<xref rid="R6" ref-type="bibr">6</xref>), also known as drug repurposing, uses the molecular structure, indications and adverse effects of a known drug to develop new functions beyond the drug testing, safety review and clinical phases of the traditional drug development model. It reduces costs and time with low risk (<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R7" ref-type="bibr">7</xref>).</p>
    <p>Using the structure, properties and target interactions to predict new functions of drugs is a key step in drug repositioning, and a key point is to know and understand the relationship between drugs and targets (<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>). The association between a drug and target gene can be determined by <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies, and a lot of drug-related databases have been constructed, such as ChEMBL (<xref rid="R10" ref-type="bibr">10</xref>), DrugBank (<xref rid="R11" ref-type="bibr">11</xref>) and DtoPdb (<xref rid="R12" ref-type="bibr">12</xref>). A variety of computational methods to predict drugâ€“target association have been proposed, such as data mining (<xref rid="R13" ref-type="bibr">13</xref>), machine learning methods (<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>), neural networks (<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R16" ref-type="bibr">16</xref>) and collaborative matrix decomposition methods (<xref rid="R9" ref-type="bibr">9</xref>). Key information used in these methods is the known experimentally confirmed drugâ€“target associations.</p>
    <p>In some drug-related databases, the associations between drugs and targets have been experimentally validated, such as DrugBank, KEGG (<xref rid="R17" ref-type="bibr">17</xref>) and PubChem (<xref rid="R18" ref-type="bibr">18</xref>). However, in some databases, in addition to experimentally confirmed drugâ€“target association, there are also computational predicted drugâ€“target associations, such as BindingDB (<xref rid="R19" ref-type="bibr">19</xref>), STITCH (<xref rid="R20" ref-type="bibr">20</xref>) and ChEMBL. We can get quite different drugâ€“target associations when using different predicting methods or thresholds. Therefore, experimentally validated drugâ€“target associations are more confident than the predicted ones and much useful in drug repositioning and other studies.</p>
    <p>The information in these databases varies a lot due to their different research purposes. SIDER and DrugBank focus on the drug structure and function, with less information on target genes (<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R21" ref-type="bibr">21</xref>). DGIdb focuses more on drugâ€“target associations without specific information on corresponding drugs and targets (<xref rid="R12" ref-type="bibr">12</xref>). STITCH and SuperPred focus on the prediction of new drug functions (<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R22" ref-type="bibr">22</xref>). PharmGKB contains too little information on experimentally validated data, while BindingDB has too much information on predicted data to meet the data needs of researchers (<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R23" ref-type="bibr">23</xref>). Meanwhile, there are different identifications for drugs and genes, and it makes extra burden for researchers when they acquire information from different databases.</p>
    <p>Here, we used unified standards for drugs and target genes, integrated the experimentally validated drugâ€“target associations in the current popular drug-related databases and constructed a highly confident drugâ€“target (HCDT (<ext-link xlink:href="http://hainmu-biobigdata.com/hcdt" ext-link-type="uri">http://hainmu-biobigdata.com/hcdt</ext-link>) database.</p>
  </sec>
  <sec id="s3">
    <title>Materials and methods</title>
    <sec id="s3-s1">
      <title>Data collection and processing</title>
      <p>We have collected 13 commonly used drug databases: BindingDB, ChEMBL, DGIdb, DrugBank, GtoPdb, PharmGKB, PubChem, TTD (<xref rid="R24" ref-type="bibr">24</xref>), CancerDR (<xref rid="R25" ref-type="bibr">25</xref>), STITCH, SIDER, SuperPred and KEGG (see details inÂ <xref rid="T1" ref-type="table">TableÂ 1</xref>). The drug-related data are expected to contain simplified molecular input line entry system (SMILES), International Union of Pure and Applied Chemists (IUPAC) name, International Chemical Identifier (INCH), The Anatomical Therapeutic Chemical codes and binding affinity of the drug; for the gene data, it is guaranteed to contain one of the gene symbols, Entrez ID, Ensembl ID or UniProt ID, which can be mapped with the gene information in the HGNC database.</p>
      <table-wrap position="float" id="T1">
        <label>TableÂ 1.</label>
        <caption>
          <p>Database information and criteria</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th valign="bottom" align="left" rowspan="1" colspan="1"/>
              <th valign="bottom" colspan="4" align="center" rowspan="1">Drug label</th>
              <th valign="bottom" colspan="5" align="center" rowspan="1">Gene label</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Database</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">SMILES</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">IUPAC name</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Inch</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">ATC codes</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Binding affinity</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Gene symbol</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Entrez ID</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Ensembl ID</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">UniProt ID</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Criteria</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">BindingDB<break/>ChEMBL<break/>GtoPdb<break/>PubChem<break/>TTD</td>
              <td align="left" rowspan="1" colspan="1">âˆš<break/>âˆš<break/>âˆš<break/>âˆš<break/>âˆš</td>
              <td align="left" rowspan="1" colspan="1">Â <break/>âˆš<break/>âˆš<break/>âˆš<break/>Â </td>
              <td align="left" rowspan="1" colspan="1">âˆš<break/>âˆš<break/>âˆš<break/>âˆš<break/>âˆš</td>
              <td align="left" rowspan="1" colspan="1">Â <break/>âˆš<break/>Â <break/>âˆš<break/>Â </td>
              <td align="left" rowspan="1" colspan="1">âˆš<break/>âˆš<break/>âˆš<break/>âˆš<break/>âˆš</td>
              <td align="left" rowspan="1" colspan="1">Â <break/>âˆš<break/>âˆš<break/>âˆš<break/>âˆš</td>
              <td align="left" rowspan="1" colspan="1">Â <break/>Â <break/>Â <break/>Â <break/>Â </td>
              <td align="left" rowspan="1" colspan="1">Â <break/>âˆš<break/>âˆš<break/>âˆš<break/>Â </td>
              <td align="left" rowspan="1" colspan="1">âˆš<break/>âˆš<break/>âˆš<break/>âˆš<break/>âˆš</td>
              <td align="left" rowspan="1" colspan="1">Including criteria (i) binding affinity, including at least one of <italic toggle="yes">K</italic><sub>i</sub>, <italic toggle="yes">K</italic><sub>d</sub>, IC<sub>50</sub> or EC<sub>50</sub>â€‰â‰¤â€‰10â€‰Î¼M; (ii) the presence of UniProt ID representation of the protein and (iii) the protein being tagged as â€˜reviewâ€™.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DGIdb</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">Fourteen of these experimentally validated database sources are screened for drugâ€“target interactions and eight are excluded. See the details in <xref rid="s6" ref-type="sec">Supplementary Table S1</xref>.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DrugBank</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">Interactions with no clear target information are excluded.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">PharmGKB</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">Only the data marked as â€˜associatedâ€™ are included.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">CancerDR</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">CancerDR database is excluded as it is mainly used for the study of drugs and sensitive cell lines, but lacks the information of the corresponding target effects.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">STITCH<break/>SuperPred</td>
              <td align="left" rowspan="1" colspan="1">âˆš<break/>âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">Â <break/>âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">Â <break/>âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">STITCH and SuperPred are excluded, as the majority of drugâ€“target association are based on computational prediction, but not confirmed by biological experiments, which do not meet the high confident purpose of this study.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">SIDER</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">SIDER database is excluded as it is used for the study of drug side effects but lacks target information.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">KEGG</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">âˆš</td>
              <td align="left" rowspan="1" colspan="1">KEGG is excluded, as the drugâ€“target information is simply collected from ChEMBL, Drugbank and PubChem, without selection or integration.</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Five of these databases were excluded in the following steps: CancerDR database is mainly used for the study of drugs and sensitive cell lines but lacks the information of the corresponding target effects; in STITCH and SuperPred, the majority of drugâ€“target associations are based on computational prediction, but not confirmed by biological experiments, which do not meet the highly confident purpose of this study; SIDER database is used for the study of drug side effects but lacks target information; In KEGG, the drugâ€“target information is simply collected from ChEMBL, DrugBank and PubChem, without selection or collation.</p>
      <p>The left eight databases were selected as the original data sources for the HCDT database. To ensure the high confidence of drugâ€“target associations, we used the following criteria: for databases with drug binding affinity information (BindingDB, ChEMBL, GtoPdb, PubChem and TTD), we retained only drugâ€“target associations that met the following three criteria (<xref rid="R22" ref-type="bibr">22</xref>): (i) binding affinity, including at least one of <italic toggle="yes">K</italic><sub>i</sub>, <italic toggle="yes">K</italic><sub>d</sub>, half maximal inhibitory concentration (IC<sub>50</sub>) or half maximal effective concentration (EC<sub>50</sub>)â€‰â‰¤â€‰10â€‰Î¼M; (ii) the presence of UniProt ID representation of the protein and (iii) the protein being tagged as â€˜reviewâ€™. DGIdb is integrated by several databases. In the latest release of DGIdb 4.0 (<xref rid="R26" ref-type="bibr">26</xref>), we screened 14 databases for experimentally validated drugâ€“target association and excluded three databases with drugâ€“target prediction and five databases (ChEMBL, DrugBank, GtoPdb, PharmGKB and TTD) that had been collected separately (see the details in <xref rid="s6" ref-type="sec">Supplementary Table S1</xref>). In PharmGKB, there were three types of drugâ€“target relationships: â€˜associatedâ€™, â€˜not associatedâ€™ and â€˜ambiguousâ€™, and only the data marked as â€˜associatedâ€™ were selected. All drugâ€“target associations are validated by <italic toggle="yes">in vivo</italic> experiments and guaranteed to be of human origin but not of other species.</p>
    </sec>
    <sec id="s3-s2">
      <title>Drug classifications</title>
      <p>There are various kinds of drug classifications in these databases. A drug may be marked as different types in different databases. For example, tisagenlecleucel (<xref rid="R27" ref-type="bibr">27</xref>), an immune agent for B-cell lymphoma, is marked as â€˜antibodyâ€™ in ChEMBL and â€˜biotechâ€™ in BindingDB. There are about 268k drugs in BindingDB, which account for 89.5% of drugs in HCDT database. Therefore, we classified drugs based on BindingDB first and then referred other classifications in other databases. There are six drug types in BindingDB: small-molecule organic compounds (synthetic small molecule), synthetic products of biotechnology (Biotech), metabolites, oligomer and combination of drug pairs and unknown drug types that do not fall into the above five categories. For Biotech, there are subtypes such as protein, cell, enzyme, gene in ChEMBL, antibody in ChEMBL and GtoPdb. For oligomer, there are four subtypes, such as oligonucleotide, oligopeptide and oligosaccharide in ChEMBL and peptide in GtoPdb. There are also two special drug types in GtoPdb. For example, apigenina (<xref rid="R28" ref-type="bibr">28</xref>), a flavonoid, is shown as a natural product in ChEMBL and GtoPdb, but does not belong to any six types in BindingDB; nitric oxide, a selective pulmonary vasodilator used to treat various forms of pulmonary hypertension in order to improve oxygenation levels, is marked as inorganic in GtoPdb, but it does not belong to any six types in BindingDB. Finally, we got eight types of drugsÂ (<xref rid="F1" ref-type="fig">FigureÂ 1</xref>).</p>
      <fig position="float" id="F1" fig-type="figure">
        <label>FigureÂ 1.</label>
        <caption>
          <p>Drug classifications in HCDT database.</p>
        </caption>
        <graphic xlink:href="baac101f1" position="float"/>
      </fig>
      <p>For each drug, we use the label in BindingDB if a drug exists in BindingDB (for example, tisagenlecleucel is marked as â€˜biotechâ€™ as it is marked as â€˜biotechâ€™ in BindingDB); we match label in the original database to the corresponding BindingDB label if a drug does not exist in BindingDB, but the labels can match [for example, MIPOMERSEN (<xref rid="R29" ref-type="bibr">29</xref>) is marked as â€˜Oligomerâ€™ as it is marked as â€˜Oligonucleotideâ€™ in ChEMBL]; we use label inorganic or natural product, if a drug belonged to these two types.</p>
    </sec>
    <sec id="s3-s3">
      <title>Gene types</title>
      <p>Based on the HGNC database, genes are classified into four groups according to function (<xref rid="R30" ref-type="bibr">30</xref>): genes that encode proteins, genes that do not encode ribonucleic acid (RNA), pseudogenes that have no actual function and the remaining genes whose function is not yet clear. Then, they are further subdivided into a total of 24 subtypes based on their specific attached functional objects. The main type of protein-coding gene group is a collection of genes that can encode proteins; the non-coding RNA group is divided into 10 types according to the RNA type that can be transcribed and translated into sex chromosomes, long-stranded non-coding RNA, microRNA and small RNA; pseudogenes are non-functional residues formed during gene evolution and can be divided into three types: T-cell receptor pseudogenes, immunoglobulin pseudogenes and pseudogenes with unknown receptors; for the other 10 subtypes such as functional T-cell receptor genes, complex site component genes and endogenous retroviral genes, they make up the fourth group because the attachment object loci are still unclear.</p>
    </sec>
    <sec id="s3-s4">
      <title>Data integration</title>
      <p>The SMILES information is used as the unique identifier (<xref rid="R31" ref-type="bibr">31</xref>) for drugs and then other features, such as IUPAC name (<xref rid="R32" ref-type="bibr">32</xref>), and synonyms are matched to the drugs. For genes, the gene symbol is used as the unique identifier and the HGNC database is used to supplement the information on UniProt ID, Entrez ID, gene type, location and Ensembl ID. The drugâ€“target relationships in each database were then integrated based on SMILES and gene symbol.</p>
    </sec>
  </sec>
  <sec id="s4">
    <title>Results</title>
    <sec id="s4-s1">
      <title>Data in HCDT database</title>
      <p>In total, 299â€‰458 drugs, 5618 genes and 500â€‰681 pairs of associations were obtained in HCDT databaseÂ (<xref rid="T2" ref-type="table">TableÂ 2</xref>). BindingDB is the largest source of HCDT database.</p>
      <table-wrap position="float" id="T2">
        <label>TableÂ 2.</label>
        <caption>
          <p>Statistics on HCDT data sources</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Database</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Number of drugs</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Number of targets</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Number of associations</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">BindingDB</td>
              <td align="left" rowspan="1" colspan="1">268â€‰001</td>
              <td align="left" rowspan="1" colspan="1">2293</td>
              <td align="left" rowspan="1" colspan="1">357â€‰695</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">ChEMBL</td>
              <td align="left" rowspan="1" colspan="1">17â€‰110</td>
              <td align="left" rowspan="1" colspan="1">1018</td>
              <td align="left" rowspan="1" colspan="1">42â€‰571</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DGIdb</td>
              <td align="left" rowspan="1" colspan="1">10â€‰025</td>
              <td align="left" rowspan="1" colspan="1">2344</td>
              <td align="left" rowspan="1" colspan="1">41â€‰924</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DrugBank</td>
              <td align="left" rowspan="1" colspan="1">6393</td>
              <td align="left" rowspan="1" colspan="1">3168</td>
              <td align="left" rowspan="1" colspan="1">27â€‰111</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Gtopdb</td>
              <td align="left" rowspan="1" colspan="1">8821</td>
              <td align="left" rowspan="1" colspan="1">1766</td>
              <td align="left" rowspan="1" colspan="1">18â€‰352</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">PharmGKB</td>
              <td align="left" rowspan="1" colspan="1">1178</td>
              <td align="left" rowspan="1" colspan="1">1868</td>
              <td align="left" rowspan="1" colspan="1">18â€‰084</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">PubChem</td>
              <td align="left" rowspan="1" colspan="1">11â€‰049</td>
              <td align="left" rowspan="1" colspan="1">3840</td>
              <td align="left" rowspan="1" colspan="1">64â€‰483</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">TTD</td>
              <td align="left" rowspan="1" colspan="1">27â€‰761</td>
              <td align="left" rowspan="1" colspan="1">2510</td>
              <td align="left" rowspan="1" colspan="1">56â€‰048</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">HCDT database</td>
              <td align="left" rowspan="1" colspan="1">299â€‰458</td>
              <td align="left" rowspan="1" colspan="1">5617</td>
              <td align="left" rowspan="1" colspan="1">500â€‰681</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="s4-s2">
      <title>Drugâ€“target network</title>
      <p>A drugâ€“target network is constructed based on the drugâ€“target association. The distribution of degrees for drug (the number of corresponding targets for a drug) is shown inÂ <xref rid="F2" ref-type="fig">FigureÂ 2</xref>. A drug is associated an average 1.7 experimentally validated target genes, and 220 198 (73.53%) drugs are associated with only the target. Staurosporine (<xref rid="R33" ref-type="bibr">33</xref>), an adenosine triphosphateâ€“competitive, non-selective protein kinase inhibitor, has up to 333 targets. Similarly, the distribution of degrees for target (the number of corresponding drugs for a target gene) is shown inÂ <xref rid="F3" ref-type="fig">FigureÂ 3</xref>. A target gene is associated an average 89.1 drugs, and 1214 (21.61%) genes are associated with only one drug. HCRTR2 has 6435 related drugs, which is the largest number (<xref rid="R34" ref-type="bibr">34</xref>). The protein encoded by HCRTR2 is a G-protein coupled receptor (GPCR), and it is involved in encoding hypothalamic secretagogues that lend themselves to the regulation of appetite and sleep behavior. GPCRs are the largest family of membrane receptors that are targeted by approved drugs, and approximately 35% of approved drugs target GPCRs (<xref rid="R35" ref-type="bibr">35</xref>). The drugs associated with HCRTR2 can be divided into activators and inhibitors. The amide carbon group for the junction is present in the activator. The amide carbonyl of the linker forms a hydrogen bond with H350, whose sidechain also contacts the terminal 1,2,3-triazole moiety and the distal phenyl ring of the core, thereby stabilizing the kinked conformation of HCRTR2. As for inhibitors, all antagonists occupy the bottom-most region of the central cavity, overlapping with the last three residues of HCRTR2 and the portion of a compound containing the sulfonamide and the amide-linked phenyltriazole (<xref rid="R36" ref-type="bibr">36</xref>). A list of hub drugs and targets is shown in <xref rid="s6" ref-type="sec">Supplementary Table S2</xref>.</p>
      <fig position="float" id="F2" fig-type="figure">
        <label>FigureÂ 2.</label>
        <caption>
          <p>A frequency plot of the number of targets for a drug. The <italic toggle="yes">x</italic>-axis indicates the number of targets corresponding to a drug and the <italic toggle="yes">y</italic>-axis indicates the number of drugs. In this figure, only the drugs with less than 15 target genes are shown which account for 99.5% of the drugs.</p>
        </caption>
        <graphic xlink:href="baac101f2" position="float"/>
      </fig>
      <fig position="float" id="F3" fig-type="figure">
        <label>FigureÂ 3.</label>
        <caption>
          <p>A frequency plot of the number of drugs targeting a specific gene. The <italic toggle="yes">x</italic>-axis indicates the number of drugs targeting a specific gene, and <italic toggle="yes">y</italic>-axis indicates the number of target genes. In this figure, only the genes with less than 20 related drugs are shown which account for 73% of the target genes.</p>
        </caption>
        <graphic xlink:href="baac101f3" position="float"/>
      </fig>
      <p>We take the top 5% of drugs and genes of degrees in the networks as hubs, where the drugs had at least four targets and the genes had at least 31 target drugs. Then, we compare the hubs between HCDT database and the eight individual databases. For genes, all hub genes in BindingDB and ChEMBL belong to HCDT database (<xref rid="s6" ref-type="sec">Supplementary Figure S1A</xref> and <xref rid="s6" ref-type="sec">B</xref>), which is because BindingDB and ChEMBL provide most drugs for HCDT database. Most hub genes (204/282) in HCDT database are hubs in these individual databases (<xref rid="s6" ref-type="sec">Supplementary Figure S1I</xref>). For drugs, all or most hub drugs in seven individual databases except BindingDB are hubs in HCDT database (<xref rid="s6" ref-type="sec">Supplementary Figure S2B-H</xref>), and about half (7305/13â€‰400) of hub drugs in BindingDB are hubs in HCDT database (<xref rid="s6" ref-type="sec">Supplementary Figure S2A</xref>). These results show that HCDT database is consistent with these individual databases and provides more information as an integrated database.</p>
    </sec>
    <sec id="s4-s3">
      <title>Drug and target classification</title>
      <p>299â€‰458 drugs were classified into eight types in HCDT databaseÂ (<xref rid="T3" ref-type="table">TableÂ 3</xref>). There are 268â€‰722 synthetic small-molecule drugs, which is in line with the reality of drug design, where small organic compounds are mostly used in clinical drug development (<xref rid="R37" ref-type="bibr">37</xref>). There are only 156 inorganic drugs. Inorganic drugs have been identified as significant candidates for new cancer therapeutic modalities because of their biocompatibility, easy functionalization and fabrication, optical tunable characteristics and chemical stability. However, the problems of eliminating long-term toxicity from metals <italic toggle="yes">in vivo</italic> and transport of drug carriers have led to the still low number of inorganic drugs entering clinical usage (<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref>).</p>
      <table-wrap position="float" id="T3">
        <label>TableÂ 3.</label>
        <caption>
          <p>Drug statistics in HCDT database</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Drug type</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Number of drugs</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Synthetic small molecule</td>
              <td align="left" rowspan="1" colspan="1">268â€‰722</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Natural productâ€“derived</td>
              <td align="left" rowspan="1" colspan="1">18â€‰864</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Biotech</td>
              <td align="left" rowspan="1" colspan="1">4978</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Oligomer</td>
              <td align="left" rowspan="1" colspan="1">2824</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Metabolite</td>
              <td align="left" rowspan="1" colspan="1">1778</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Inorganic</td>
              <td align="left" rowspan="1" colspan="1">156</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Combination drug</td>
              <td align="left" rowspan="1" colspan="1">439</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Unknown</td>
              <td align="left" rowspan="1" colspan="1">1697</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Total</td>
              <td rowspan="1" colspan="1">299â€‰458</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>5618 target genes are classified into 11 subtypes in HCDT databaseÂ (<xref rid="T4" ref-type="table">TableÂ 4</xref>), and 5492 of them (97.8%) are protein-coding genes. Different types of genes have different functional mechanisms in drug effect, and HCDT database could be used to analyze the potential mechanism for drugs.</p>
      <table-wrap position="float" id="T4">
        <label>TableÂ 4.</label>
        <caption>
          <p>Types of genes in HCDT database</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Gene type</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Number of genes</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Gene with protein product</td>
              <td align="left" rowspan="1" colspan="1">5492</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Pseudogene</td>
              <td align="left" rowspan="1" colspan="1">39</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">RNA, micro</td>
              <td align="left" rowspan="1" colspan="1">28</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Immunoglobulin gene</td>
              <td align="left" rowspan="1" colspan="1">21</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">RNA, long non-coding</td>
              <td align="left" rowspan="1" colspan="1">18</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Complex locus constituent</td>
              <td align="left" rowspan="1" colspan="1">9</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">T cell receptor gene</td>
              <td align="left" rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Readthrough</td>
              <td align="left" rowspan="1" colspan="1">4</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">RNA, small nucleolar</td>
              <td align="left" rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">RNA, misc</td>
              <td align="left" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">RNA, ribosomal</td>
              <td align="left" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Total</td>
              <td align="left" rowspan="1" colspan="1">5618</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="s4-s4">
      <title>Comparison with individual databases</title>
      <p>HCDT database is an integrated normative database, and it includes as much information as possible for drugs and target genes. For each drug, there are SMILES, PubChem Compound ID, IUPAC name, synonyms, INCH and drug type. For each gene, there are gene symbol, Ensembl ID, gene type, location, Entrez ID and UniPort ID. Not every information exists in these individual databases. For example, in ChEMBL, the target genes are represented by gene-encoded proteins, but not gene symbols; similarly, SMILES and IUPAC name information of some drugs in BindingDB are missing. Therefore, HCDT database is much convenient for researchers.</p>
      <p>Compared to individual databases, HCDT database has a much greater volume. It contains 1.1â€“254.2 times drugs, 1.8â€“5.5 times target genes and 1.4â€“27.7 times drugâ€“target associations. Among these databases, BindingDB is the largest data provider, which accounts for 89.50% of drugs, 40.82% of target genes and 71.44% of drugâ€“target associations. For individual databases, there are different types of data information for drugs, targets and associations depending on the purpose of the study. For example, DrugBank lacks target structure information; DGIPdb has descriptions of associations but lacks drug-specific information; BindingDB has records of both drug and target information but is more complicated to operate and has a lot of prediction information. HCDT database combines the advantages of each database and complements the drug, target and association information.</p>
      <p>In HCDT database, 399â€‰429 (79.78%) drugâ€“target associations came from only one raw database, most associations (99.21%) existed in less than four raw databases and only 48 associations were present in all eight databasesÂ (<xref rid="F4" ref-type="fig">FigureÂ 4</xref>). For example, amitriptyline is a commonly used antidepressant in various types of depression as well as in chronic pain (<xref rid="R40" ref-type="bibr">40</xref>). The association of amitriptyline with CACNA1C is only recorded in BindingDB, the association of amitriptyline with Potassium Voltage-Gated Channel Subfamily H Member 2 is recorded in BindingDB, DrugBank and PubChem and the association of amitriptyline with SLC6A4 is recorded in all eight databases. This indicates that the drugâ€“target associations in each database are somewhat related but have some variability due to the different purposes of each database. Integration of these databases in HCDT database greatly improves the volume and credibility of drugâ€“target associations.</p>
      <fig position="float" id="F4" fig-type="figure">
        <label>FigureÂ 4.</label>
        <caption>
          <p>Histogram of the number of data sources for each drugâ€“target association. The <italic toggle="yes">x</italic>-axis indicates the number of data sources for each drugâ€“target association, and the <italic toggle="yes">y</italic>-axis indicates the number of drugâ€“target associations.</p>
        </caption>
        <graphic xlink:href="baac101f4" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="s5">
    <title>Discussion</title>
    <p>Drugâ€“target association plays more and more roles in drug discovery, drug repositioning, drug synergy prediction, etc. HCDT database (<ext-link xlink:href="http://hainmu-biobigdata.com/hcdt" ext-link-type="uri">http://hainmu-biobigdata.com/hcdt</ext-link>) is a publicly available resource for highly confident drugâ€“target associations. The researchers can query drugâ€“target associations via drugs or target genes and can download all the associations. HCDT database integrated eight databases and includes 500â€‰681 highly confident (experimental verified) drugâ€“target associations. It has the largest volume and has as much information as possible for drugs and target genes. Together with multi-omics data, it will be a good resource in analyzing the drug functional mechanism, mining drug-related biological pathway, predicting drug synergy, etc.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>baac101_Supp</label>
      <media xlink:href="baac101_supp.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>The authors thank all the anonymous referees for their valuable suggestions and support.</p>
  </ack>
  <sec id="s6">
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Database</italic> Online.</p>
  </sec>
  <sec id="s7">
    <title>Funding</title>
    <p>Major Science and Technology Program of Hainan Province (No. ZDKJ202003), National Natural Science Foundation of China (No. 32260155, 31701159 and 32160179), the Natural Science Foundation of Hainan Province (No. 621MS041, 821MS045, 821MS0777 and 822MS074); the Education Department of Hainan Province [No.Hnky2022-32]; the Innovation Fund for Postgraduates of Hainan Medical University (HYYS2021B12).</p>
  </sec>
  <sec id="s8">
    <title>Conflict of interest</title>
    <p>The authors declare no conflict of interest.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="R1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xue</surname><given-names>H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>H.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2018</year>) <article-title>Review of drug repositioning approaches and resources</article-title>. <source><italic toggle="yes">Int. J. Biol. Sci.</italic></source>, <volume>14</volume>, <fpage>1232</fpage>â€“<lpage>1244</lpage>.<pub-id pub-id-type="pmid">30123072</pub-id></mixed-citation>
    </ref>
    <ref id="R2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sertkaya</surname><given-names>A.</given-names></string-name>, <string-name><surname>Birkenbach</surname><given-names>A.</given-names></string-name>, <string-name><surname>Berlind</surname><given-names>A.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2014</year>) <article-title>Examination of clinical trial costs and barriers for drug development</article-title>. <source>US Department of health and human services, office of the assistant secretary for planning and evaluation report</source>. <volume>1</volume>, <fpage>1</fpage>â€“<lpage>92</lpage>.</mixed-citation>
    </ref>
    <ref id="R3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yeu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yoon</surname><given-names>Y.</given-names></string-name> and <string-name><surname>Park</surname><given-names>S.</given-names></string-name></person-group> (<year>2015</year>) <article-title>Protein localization vector propagation: a method for improving the accuracy of drug repositioning</article-title>. <source><italic toggle="yes">Mol. Biosyst.</italic></source>, <volume>11</volume>, <fpage>2096</fpage>â€“<lpage>2102</lpage>.<pub-id pub-id-type="pmid">25998487</pub-id></mixed-citation>
    </ref>
    <ref id="R4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Darrow</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Avorn</surname><given-names>J.</given-names></string-name> and <string-name><surname>Kesselheim</surname><given-names>A.S.</given-names></string-name></person-group> (<year>2020</year>) <article-title>FDA approval and regulation of pharmaceuticals, 1983â€“2018</article-title>. <source><italic toggle="yes">JAMA</italic></source>, <volume>323</volume>, <fpage>164</fpage>â€“<lpage>176</lpage>.<pub-id pub-id-type="pmid">31935033</pub-id></mixed-citation>
    </ref>
    <ref id="R5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wouters</surname><given-names>O.J.</given-names></string-name>, <string-name><surname>McKee</surname><given-names>M.</given-names></string-name> and <string-name><surname>Luyten</surname><given-names>J.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Estimated research and development investment needed to bring a new medicine to market, 2009-2018</article-title>. <source><italic toggle="yes">JAMA</italic></source>, <volume>323</volume>, <fpage>844</fpage>â€“<lpage>853</lpage>.<pub-id pub-id-type="pmid">32125404</pub-id></mixed-citation>
    </ref>
    <ref id="R6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ashburn</surname><given-names>T.T.</given-names></string-name> and <string-name><surname>Thor</surname><given-names>K.B.</given-names></string-name></person-group> (<year>2004</year>) <article-title>Drug repositioning: identifying and developing new uses for existing drugs</article-title>. <source><italic toggle="yes">Nat. Rev. Drug Discov.</italic></source>, <volume>3</volume>, <fpage>673</fpage>â€“<lpage>683</lpage>.<pub-id pub-id-type="pmid">15286734</pub-id></mixed-citation>
    </ref>
    <ref id="R7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nosengo</surname><given-names>N.</given-names></string-name></person-group> (<year>2016</year>) <article-title>Can you teach old drugs new tricks?</article-title><source><italic toggle="yes">Nature</italic></source>, <volume>534</volume>, <fpage>314</fpage>â€“<lpage>316</lpage>.<pub-id pub-id-type="pmid">27306171</pub-id></mixed-citation>
    </ref>
    <ref id="R8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verbaanderd</surname><given-names>C.</given-names></string-name>, <string-name><surname>Meheus</surname><given-names>L.</given-names></string-name>, <string-name><surname>Huys</surname><given-names>I.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2017</year>) <article-title>Repurposing drugs in oncology: next steps</article-title>. <source><italic toggle="yes">Trends Cancer</italic></source>, <volume>3</volume>, <fpage>543</fpage>â€“<lpage>546</lpage>.<pub-id pub-id-type="pmid">28780930</pub-id></mixed-citation>
    </ref>
    <ref id="R9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>X.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2016</year>) <article-title>Drug-target interaction prediction: databases, web servers and computational models</article-title>. <source><italic toggle="yes">Brief. Bioinform.</italic></source>, <volume>17</volume>, <fpage>696</fpage>â€“<lpage>712</lpage>.<pub-id pub-id-type="pmid">26283676</pub-id></mixed-citation>
    </ref>
    <ref id="R10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mendez</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gaulton</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bento</surname><given-names>A.P.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2019</year>) <article-title>ChEMBL: towards direct deposition of bioassay data</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>47</volume>, <fpage>D930</fpage>â€“<lpage>D940</lpage>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="R11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2018</year>) <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>46</volume>, <fpage>D1074</fpage>â€“<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="R12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harding</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Faccenda</surname><given-names>E.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2022</year>) <article-title>The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>50</volume>, <fpage>D1282</fpage>â€“<lpage>D1294</lpage>.<pub-id pub-id-type="pmid">34718737</pub-id></mixed-citation>
    </ref>
    <ref id="R13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iwata</surname><given-names>H.</given-names></string-name>, <string-name><surname>Sawada</surname><given-names>R.</given-names></string-name>, <string-name><surname>Mizutani</surname><given-names>S.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2015</year>) <article-title>Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data</article-title>. <source><italic toggle="yes">J. Chem. Inf. Model</italic></source>, <volume>55</volume>, <fpage>446</fpage>â€“<lpage>459</lpage>.<pub-id pub-id-type="pmid">25602292</pub-id></mixed-citation>
    </ref>
    <ref id="R14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Issa</surname><given-names>N.T.</given-names></string-name>, <string-name><surname>Stathias</surname><given-names>V.</given-names></string-name>, <string-name><surname>Schurer</surname><given-names>S.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>Machine and deep learning approaches for cancer drug repurposing</article-title>. <source><italic toggle="yes">Semin. Cancer Biol.</italic></source>, <volume>68</volume>, <fpage>132</fpage>â€“<lpage>142</lpage>.<pub-id pub-id-type="pmid">31904426</pub-id></mixed-citation>
    </ref>
    <ref id="R15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname><given-names>L.</given-names></string-name>, <string-name><surname>Shukla</surname><given-names>T.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2020</year>) <article-title>Machine learning methods in drug discovery</article-title>. <source><italic toggle="yes">Molecules</italic></source>, <volume>25</volume>, <page-range>5277</page-range>.</mixed-citation>
    </ref>
    <ref id="R16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>H.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Big data and artificial intelligence modeling for drug discovery</article-title>. <source><italic toggle="yes">Annu. Rev. Pharmacol. Toxicol.</italic></source>, <volume>60</volume>, <fpage>573</fpage>â€“<lpage>589</lpage>.<pub-id pub-id-type="pmid">31518513</pub-id></mixed-citation>
    </ref>
    <ref id="R17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Furumichi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sato</surname><given-names>Y.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>KEGG: integrating viruses and cellular organisms</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>49</volume>, <fpage>D545</fpage>â€“<lpage>D551</lpage>.<pub-id pub-id-type="pmid">33125081</pub-id></mixed-citation>
    </ref>
    <ref id="R18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>T.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>PubChem in 2021: new data content and improved web interfaces</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>49</volume>, <fpage>D1388</fpage>â€“<lpage>D1395</lpage>.<pub-id pub-id-type="pmid">33151290</pub-id></mixed-citation>
    </ref>
    <ref id="R19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gilson</surname><given-names>M.K.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Baitaluk</surname><given-names>M.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2016</year>) <article-title>BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>44</volume>, <fpage>D1045</fpage>â€“<lpage>D1053</lpage>.<pub-id pub-id-type="pmid">26481362</pub-id></mixed-citation>
    </ref>
    <ref id="R20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szklarczyk</surname><given-names>D.</given-names></string-name>, <string-name><surname>Santos</surname><given-names>A.</given-names></string-name>, <string-name><surname>von Mering</surname><given-names>C.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2016</year>) <article-title>STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>44</volume>, <fpage>D380</fpage>â€“<lpage>384</lpage>.<pub-id pub-id-type="pmid">26590256</pub-id></mixed-citation>
    </ref>
    <ref id="R21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuhn</surname><given-names>M.</given-names></string-name>, <string-name><surname>Letunic</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>L.J.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2016</year>) <article-title>The SIDER database of drugs and side effects</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>44</volume>, <fpage>D1075</fpage>â€“<lpage>D1079</lpage>.<pub-id pub-id-type="pmid">26481350</pub-id></mixed-citation>
    </ref>
    <ref id="R22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nickel</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gohlke</surname><given-names>B.O.</given-names></string-name>, <string-name><surname>Erehman</surname><given-names>J.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2014</year>) <article-title>SuperPred: update on drug classification and target prediction</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>42</volume>, <fpage>W26</fpage>â€“<lpage>W31</lpage>.<pub-id pub-id-type="pmid">24878925</pub-id></mixed-citation>
    </ref>
    <ref id="R23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbarino</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Whirl-Carrillo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Altman</surname><given-names>R.B.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2018</year>) <article-title>PharmGKB: a worldwide resource for pharmacogenomic information</article-title>. <source><italic toggle="yes">Wiley Interdiscip. Rev. Syst. Biol. Med.</italic></source>, <volume>10</volume>, <page-range>e1417</page-range>.</mixed-citation>
    </ref>
    <ref id="R24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ji</surname><given-names>Z.L.</given-names></string-name> and <string-name><surname>Chen</surname><given-names>Y.Z.</given-names></string-name></person-group> (<year>2002</year>) <article-title>TTD: Therapeutic Target Database</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>30</volume>, <fpage>412</fpage>â€“<lpage>415</lpage>.<pub-id pub-id-type="pmid">11752352</pub-id></mixed-citation>
    </ref>
    <ref id="R25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname><given-names>R.</given-names></string-name>, <string-name><surname>Chaudhary</surname><given-names>K.</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>S.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2013</year>) <article-title>CancerDR: cancer drug resistance database</article-title>. <source><italic toggle="yes">Sci. Rep.</italic></source>, <volume>3</volume>, <page-range>1445</page-range>.</mixed-citation>
    </ref>
    <ref id="R26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freshour</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Kiwala</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cotto</surname><given-names>K.C.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>49</volume>, <fpage>D1144</fpage>â€“<lpage>D1151</lpage>.<pub-id pub-id-type="pmid">33237278</pub-id></mixed-citation>
    </ref>
    <ref id="R27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maude</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Laetsch</surname><given-names>T.W.</given-names></string-name>, <string-name><surname>Buechner</surname><given-names>J.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2018</year>) <article-title>Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia</article-title>. <source><italic toggle="yes">N. Engl. J. Med.</italic></source>, <volume>378</volume>, <fpage>439</fpage>â€“<lpage>448.</lpage><pub-id pub-id-type="pmid">29385370</pub-id></mixed-citation>
    </ref>
    <ref id="R28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Min</surname><given-names>S.Y.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H.W.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2020</year>) <article-title>Effects of apigenin on RBL-2H3, RAW264.7, and HaCaT cells: anti-allergic, anti-inflammatory, and skin-protective activities</article-title>. <source><italic toggle="yes">Int. J. Mol. Sci.</italic></source>, <volume>21</volume>, <page-range>4620</page-range>.</mixed-citation>
    </ref>
    <ref id="R29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Astaneh</surname><given-names>B.</given-names></string-name>, <string-name><surname>Makhdami</surname><given-names>N.</given-names></string-name>, <string-name><surname>Astaneh</surname><given-names>V.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>The effect of mipomersen in the management of patients with familial hypercholesterolemia: a systematic review and meta-analysis of clinical trials</article-title>. <source><italic toggle="yes">J. Cardiovasc. Dev. Dis.</italic></source>, <volume>8</volume>, <page-range>82</page-range>.</mixed-citation>
    </ref>
    <ref id="R30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tweedie</surname><given-names>S.</given-names></string-name>, <string-name><surname>Braschi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname><given-names>K.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>Genenames.org: the HGNC and VGNC resources in 2021</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>49</volume>, <fpage>D939</fpage>â€“<lpage>D946</lpage>.<pub-id pub-id-type="pmid">33152070</pub-id></mixed-citation>
    </ref>
    <ref id="R31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kpanou</surname><given-names>R.</given-names></string-name>, <string-name><surname>Osseni</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Tossou</surname><given-names>P.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>On the robustness of generalization of drug-drug interaction models</article-title>. <source><italic toggle="yes">BMC Bioinform.</italic></source>, <volume>22</volume>, <page-range>477</page-range>.</mixed-citation>
    </ref>
    <ref id="R32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rajan</surname><given-names>K.</given-names></string-name>, <string-name><surname>Zielesny</surname><given-names>A.</given-names></string-name> and <string-name><surname>Steinbeck</surname><given-names>C.</given-names></string-name></person-group> (<year>2021</year>) <article-title>STOUT: SMILES to IUPAC names using neural machine translation</article-title>. <source><italic toggle="yes">J. Cheminform.</italic></source>, <volume>13</volume>, <page-range>34</page-range>.</mixed-citation>
    </ref>
    <ref id="R33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ye</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Lei</surname><given-names>X.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2020</year>) <article-title>Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis</article-title>. <source><italic toggle="yes">Theranostics</italic></source>, <volume>10</volume>, <fpage>7545</fpage>â€“<lpage>7560</lpage>.<pub-id pub-id-type="pmid">32685004</pub-id></mixed-citation>
    </ref>
    <ref id="R34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dashti</surname><given-names>H.S.</given-names></string-name>, <string-name><surname>Daghlas</surname><given-names>I.</given-names></string-name>, <string-name><surname>Lane</surname><given-names>J.M.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>Genetic determinants of daytime napping and effects on cardiometabolic health</article-title>. <source><italic toggle="yes">Nat. Commun.</italic></source>, <volume>12</volume>, <page-range>900</page-range>.</mixed-citation>
    </ref>
    <ref id="R35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sriram</surname><given-names>K.</given-names></string-name> and <string-name><surname>Insel</surname><given-names>P.A.</given-names></string-name></person-group> (<year>2018</year>) <article-title>G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?</article-title><source><italic toggle="yes">Mol. Pharmacol.</italic></source>, <volume>93</volume>, <fpage>251</fpage>â€“<lpage>258</lpage>.<pub-id pub-id-type="pmid">29298813</pub-id></mixed-citation>
    </ref>
    <ref id="R36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hong</surname><given-names>C.</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>N.J.</given-names></string-name>, <string-name><surname>Zamlynny</surname><given-names>B.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2021</year>) <article-title>Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation</article-title>. <source><italic toggle="yes">Nat. Commun.</italic></source>, <volume>12</volume>, <page-range>815</page-range>.</mixed-citation>
    </ref>
    <ref id="R37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Q.</given-names></string-name> and <string-name><surname>Kang</surname><given-names>C.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Mechanisms of action for small molecules revealed by structural biology in drug discovery</article-title>. <source><italic toggle="yes">Int. J. Mol. Sci.</italic></source>, <volume>21</volume>, <page-range>5262</page-range>.</mixed-citation>
    </ref>
    <ref id="R38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jahangirian</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kalantari</surname><given-names>K.</given-names></string-name>, <string-name><surname>Izadiyan</surname><given-names>Z.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2019</year>) <article-title>A review of small molecules and drug delivery applications using gold and iron nanoparticles</article-title>. <source><italic toggle="yes">Int. J. Nanomed.</italic></source>, <volume>14</volume>, <fpage>1633</fpage>â€“<lpage>1657</lpage>.</mixed-citation>
    </ref>
    <ref id="R39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Naz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Shamoon</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>R.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2019</year>) <article-title>Advances in therapeutic implications of inorganic drug delivery nano-platforms for cancer</article-title>. <source><italic toggle="yes">Int. J. Mol. Sci.</italic></source>, <volume>20</volume>, <page-range>965</page-range>.</mixed-citation>
    </ref>
    <ref id="R40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moore</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Derry</surname><given-names>S.</given-names></string-name>, <string-name><surname>Aldington</surname><given-names>D.</given-names></string-name></person-group><etal>etÂ al.</etal> (<year>2015</year>) <article-title>Amitriptyline for neuropathic pain in adults</article-title>. <source><italic toggle="yes">Cochrane Database Syst. Rev.</italic></source>, <volume>2015</volume>, <page-range>CD008242</page-range>.</mixed-citation>
    </ref>
  </ref-list>
</back>
